Abstract: Vitiligo is an autoimmune disease present with pigment cell damage related white patch for both skin and mucosa, which is easy to diagnose and difficult to treat. Current treatment options are mostly off-label and lack specific therapeutic drugs. In recent years, several studies have shown that systemic and topical targeted immunotherapy, including biological agents and small-molecule inhibitors, are effective in the treatment of vitiligo, shedding new light on the treatment of vitiligo. We review the clinical studies of systemic and topical targeted immunotherapy in recent years to add knowledge for the clinical treatment of vitiligo.

Key words: vitiligo, targeted immunotherapy, biological agent, small-molecule inhibitor